The pathophysiological role of novel pulmonary arterial hypertension gene
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
12
11
2020
accepted:
08
02
2021
pubmed:
27
2
2021
medline:
28
10
2021
entrez:
26
2
2021
Statut:
epublish
Résumé
Pulmonary arterial hypertension (PAH) is a progressive disease predominantly targeting pre-capillary blood vessels. Adverse structural remodelling and increased pulmonary vascular resistance result in cardiac hypertrophy and ultimately failure of the right ventricle. Recent whole-genome and whole-exome sequencing studies have identified
Identifiants
pubmed: 33632800
pii: 13993003.04172-2020
doi: 10.1183/13993003.04172-2020
pii:
doi:
Substances chimiques
SOX17 protein, human
0
SOXF Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : British Heart Foundation
ID : FS/15/59/31839
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/18/2/33446
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/19/17/34275
Pays : United Kingdom
Informations de copyright
Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.
Déclaration de conflit d'intérêts
Conflict of interest: Y. Wu has nothing to disclose. Conflict of interest: J. Wharton has nothing to disclose. Conflict of interest: R. Walters has nothing to disclose. Conflict of interest: E. Vasilaki has nothing to disclose. Conflict of interest: J. Aman has nothing to disclose. Conflict of interest: L. Zhao has nothing to disclose. Conflict of interest: M.R. Wilkins has nothing to disclose. Conflict of interest: C.J. Rhodes reports personal fees from Actelion and United Therapeutics, outside the submitted work.